Meeting
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
Authors
A. Dimitrios Dimitrios Colevas
Stanford Cancer Center, Stanford, CA
A. Dimitrios Dimitrios Colevas , José Dinis , Venessa T Chin , Diogo Alpuim Costa , John J. Park , Bruno Fang , Minh Duc Phan , Yiran Zhang , Lance U'Ren , Jared Odegard , Kelly Kevelin Curtis , Erika Pirtle , Douglas Adkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04854499
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS6102)
DOI
10.1200/JCO.2023.41.16_suppl.TPS6102
Abstract #
TPS6102
Poster Bd #
93b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 2 multi-arm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE Lung and UC.
First Author: Vivek Subbiah
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs
Poster
2023 ASCO Annual Meeting
A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.
First Author: Natalie Rainey
Poster
2015 ASCO Annual Meeting
Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
First Author: Athanassios Argiris